Across TCGA pan-cancer cohorts, NPIPB15 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated NPIPB15 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher NPIPB15 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NPIPB15 expression acts as an unfavorable survival marker.

LIHC and SKCM are the cancer types where NPIPB15 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
SKCM	DFS	Median	All	0.176	0.622	.001	9	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: NPIPB15 tumor-vs-normal RNA expression · all NPIPB15 data types